Comments for PLOS Currents Evidence on Genomic Tests

Comment on Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature by mapleleaf007

mapleleaf007 — Tue, 29 Mar 2016 17:55:58 +0000

Thanks for reply. Will this test be offered outside the USA, specifically Canada?

Comment on Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature by sbrower

sbrower — Thu, 10 Mar 2016 19:16:53 +0000

We appreciate your question. GeneFx Lung is scheduled to launch in the second half of 2016. Helomics accepts all insurance plans; however, each individual’s coverage and benefit plan is unique. Our team of experts will exhaust all efforts to obtain payment for Helomics services provided to you.

Comment on Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFx® Lung Signature by mapleleaf007

mapleleaf007 — Tue, 09 Feb 2016 23:26:48 +0000

Anyone know when this test will become available and will it be covered by insurance providers?

Comment on Use of Oncotype DX in Women with Node-Positive Breast Cancer by Heather Jackson

Heather Jackson — Mon, 27 Jan 2014 18:11:10 +0000

Very throughout and informative, will definitely use this for my research on breast cancer.

Comment on Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test by Narayana Rao

Narayana Rao — Fri, 10 Jun 2011 19:26:59 +0000

Added the knol to top knols of 2011 collection — https://knol.google.com/k/-/-/2utb2lsm2k7a/2387You need to add categories to your knol. You can add Health and Science as main categories.

Comment on Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test by Alisha Lopej

Alisha Lopej — Thu, 12 May 2011 23:16:55 +0000

Colorectal cancer — Today, several test are available to colorectal cancer. When a patient shows the symptoms of this cancer, his or her doctor can screen for the disease using one of several tests such as Fecal Occult Blood Test, Flexible-Sigmoidoscopy, Double Contrast Barium Enema, Colonoscopy and DNA-Based stool test. A current study shows that a simple urine test can also detect this caner. https://www.justcancer.org/colorectal-cancer-urine-test-fine-tunes-simplifies-earlier-disease-detection.html

Comment on Genetic risk profiling for prediction of type 2 diabetes by sergio stagnaro

sergio stagnaro — Mon, 02 May 2011 02:30:28 +0000

Gene Mutations parallel Biological Alterations: The New War against Five Stages of type 2 Diabetes Mellitus. — Dear Friends, first of all, I emphasise here once again that gene mutations bring about necessarily modifications of biological functions, bedside assessed in a reliable manner, as I have demonstrated earlier (Stagnaro Sergio. Biological System Functional Modification parallels Gene Mutation. https://www.Nature.com, March 13, 2008,https://blogs.nature.com/nm/spoonful/2008/03/gout_gene.html). Secondly, according to WHO competent Authorities, there were in 2010 250 milion of diabetics, and they will be 366 milion in 2030, indicating that type 2 DM is today’s growing epidemics (1-15). In my opinion, as far as diabetes is concerned, pre-primary (analogously to the Manuel’s Story, https://www.sisbq.org/qbs-magazine.html), as well as primary prevention, especially when initiated in the first two stages among the five of the natural history of the disease, is far better than therapy, as usually. Unfortunately, Diabetic “and” Dislipidemic Constitutions, conditio sine qua non of type 2 DM, are nowadays unfortunately overlooked by the majority of physicians all around the world (12-14). A long well established clinical experience allows me to state that with the aid of Quantum Biophysical Semeiotics, physicians can quickly and easili bedside recognize the “microcirculatory remodelling”, based on newborn-pathological, subtype a) oncological , and b), aspecific, type I, Endoarteriolar Blocking Devices in tissue, wherein does really exist the inherited real risk of human common and severe diseases, as diabetes (12-15). Obviously that happens in individuals with defined Biophysical Semeiotics Constitutions, in our case, Diabetic “and” Dislipidaemic, according to Joslin(1-6, 12-15). To realize on vast scale Diabetes both Pre-Primary, and Primary Prevention (PP),enrolling exclusively individuals at type 2 DM Inherited Real Risk, we need new clinical tools, aiming to lower the increasing number of patients, because the present, expensive screening has failed (14). For instance, in the normal Langheran’s islets microcirculatory bed, there are exclusively “normal” type II (= in arterioles, according to Hammersen), but not type I (= in small arterioles) endoarteriolar blocking devices, i.e. EBD, of first and second classes, according to S.B.Curri (See https://www.semeioticabiofisica.it/microangiologia). In health, i.e., not involved by Diabetic Constitution, we cannot observe type I, newborn- pathological, EBD in above-mentioned biological system. On the contrary, in individuals involved by diabetic constitution as well as diabetic “Inherited Real Risk” and overt diabetes, of course, we observe with the aid of Quantum Biophysical Semeiotics also type I, newborn-pathological, subtype b) a-specific , EBD, facilitating the diagnosis and consequently diabetes primary prevention. In addition, the evaluation of Insulin Secretion Acute Pick Renal Test is significantly impaired, corroborating the clinical diagnosis (1-3) (See above cited- website, Practical Applications, and Glossary). Finally, an interesting clinical tool in recognizing diabetic constitution -dependent inherited real risk, as well as in diagnosing diabetes since early stages and diabetic monitoring proved to be bedside Biophysical-Semeiotic Osteocalcin Test and Siniscalchi’s Sign (10, 15) As a matter of fact, Pre-hypertension during Young Adulthood may be involved by Coronary Calcium Later in Life exclusively in presence of Inherited Real Risk of CAD, typical for individuals with lithyasic Constitution, present in about 50% OF ALL CASES OF Pre-Metabolic and Metabolic Syndrome (www.semeioticabiofisica.it; Constitutions and Bibliography). Considering the frequent association between hypertension and diabetes, more important, in my opinion based on 53-year-long clinical experience, is bedside recognizing diabetic predisposition, now-a-days possible since birth, utilising a lot of methods, different in difficulty, but all reliable. For the first time, from the clinical view-point, I have recently illustrated an original manoeuvre, based on a singular activity of osteocalcin, and reliable in bedside detecting diabetes in one minute, with the aid of a stethoscope (10). In fact, osteocalcin, a product of osteoblasts, among other action mechanisms, stimulates both insulin secretion and insulin receptor sensitivity. As a consequence, osteocalcin, secreted by above-mentioned bone cells during mean-intense lasting digital pressure – for instance – applied upon lumbar vertebrae, brings about increasing pancreatic diameters, i.e., technically speaking, type I, associated, Langherans’s islet microcirculatory activation, so that doctors assess pancreas size augmentation, which in health, lasts 10 seconds exactly (1-11). After that, pancreas diameters return to basal value for 3 sec. The second pancreas size increasing lasts 20 sec., and finally the third show the highest value: 30 sec. I terme such as clinical investigation. On the contrary, in case of diabetic constitution (3, 4, 11, 13) the…

Comment on Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test by sergio stagnaro

sergio stagnaro — Wed, 20 Apr 2011 08:34:06 +0000

Colon Cancer screening? Why not Colon Cancer Primary Prevention? — Some years ago, the health secretary, John Reid, announced a national screening programme for bowel cancer, introduced in England from April 2006 (1). Unfortunately, however, such screening was carried out in “all” individuals over 40 years old, and was based as usually on faecal occult blood testing, which looks for blood in stool samples, and flexible sigmoidoscopy, which could allow careful examination of the bowel. I foresaw that also that screening would be resulted an expensive flop, like that based on CT scanning, since World Health Authorities, in England as well as in Italy, overlook the real existence of Oncological Terrain-Dependent, Inherited Real Risk, e.g., of bowel cancer (2). In fact, I described formerly a lot of biophysical-semeiotic constitutions, among them oncological constitution (2, 6-9) As regards bowel cancer primary prevention, I can state what recently wrote on the “clinical” war against gastric cancer (4, 9), wherein I illustrated my personal “Weltanshauung”, based on 55 year long clinical experience, illustrating a clinical sign: Berretti’s Sign. Really, screening, even correctly, as well as rationally implemented, i.e., exclusively in individuals affected by both Oncological Terrain-Dependent Inherited Real Risk, is remarkable and price-worthy, but primary prevention is better for people (5, 6-13). In conclusion, aiming to defeat Colon Cancer we need a clinical tool, which allows us to bedside recognize individuals involved by real inherited risk, to enrol in primary prevention .Sergio Stagnarowww.semeioticabiofisica.it References1) Mayor S. England to start national bowel cancer screening programme BMJ 2004;329:1061 (6 November), doi:10.1136/bmj.329.7474.1061-a 2) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004. https://www.travelfactory.it/semeiotica_biofisica.htm 3) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico- Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004. 4) Stagnaro S. Oncological terrain plays a paramount role in the war against gastric cancer. https://www.biomedcentral.com/1471- 230X/4/28/comments#87454 5) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno Oncologico e del Reale Rischio Oncologico. Ediz. Travel Factory, Roma, 2004.6) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, https://www.travelfactory.it, Roma, Luglio 2009.7) Stagnaro Sergio. Colon Cancer Oncological Terrain-Dependent Inherited Real Risk. Ann. Int. Med. (15 April 2009), https://www.annals.org/cgi/eletters/150/7/4658) Stagnaro Sergio. Single Patient Based Medicine: its paramount role in Future Medicine. Public Library of Science. https://www.plosmedicine.org/annotation/listThread.action?inReplyTo=info:doi/10.1371/annotation/0e440745-6bfb-4690-a0c9-92b77057b539&root=info:doi/10.1371/annotation/0e440745-6bfb-4690-a0c9-92b77057b539 9) Sergio Stagnaro. Segno di Berretti: Diagnosi Semeiotica-Biofisica-Quantistica del Cancro Colon-Rettale, ad Iniziare Dal Reale Rischio Congenito. https://www.altrogiornale.org, 9 aprile 2010. https://www.altrogiornale.org/news.php?extend.598310) Simone Caramel and Sergio Stagnaro (2011) The role of glycocalyx in QBS diagnosis of Di Bella’s Oncological Terrain – https://www.sisbq.org/uploads/5/6/8/7/5687930/oncological_glycocalyx2011.pdf12) Simone Caramel and Sergio Stagnaro (2011) Quantum Biophysical Semeiotics of Oncological Inherited Real Risk of Myelopathy: The diagnostic role of glycocalyx. https://www.sisbq.org/uploads/5/6/8/7/5687930/qbs_myelopathy_glycocalyx_english.pdf13) Simone Caramel and Sergio Stagnaro (2011) Quantum Biophysical Semeiotics and mit-Genome’s fractal dimension Journal of Quantum Biophysical Semeiotics, 1 1-27,https://www.sisbq.org/uploads/5/6/8/7/5687930/joqbs_mitgenome.pdf